论文部分内容阅读
目的:探讨雅施达与普罗布考联合应用对高血压患者动态的动脉硬化指数及血致动脉硬化指数的影响。方法:87例患者每天清晨8时顿服培多普利4mg,治疗1周后,如舒张压仍》90mmHg者,计量增加到8mg/d,顿服,疗程8周。同时服用降血脂药普罗布考片0.5g,1天2次。治疗前后各查24小时动态血压监测及血脂五项。进行统计学处理及相关分析。结果:应用8周后,AASI、AIP明显下降,2者具有显著正相关性,有效延缓和控制了高血压和动脉硬化等心血管疾病的发展进程,降低了心血管危险因素及靶器官损伤。亦提示AASI、AIP是高血压及动脉硬化的临床防治以及为临床对高血压的风险因素早期采取措施进行干预疗效观察有效地而敏感的指标。
Objective: To investigate the effect of combination of Yasuda and probucol on the dynamic arteriosclerosis index and blood-induced arteriosclerosis index in hypertensive patients. Methods: Eighty-seven patients were treated with 4 mg of perindopril daily for 8 weeks. After one week of treatment, if the diastolic blood pressure was still 90 mmHg, the dosage was increased to 8 mg per day for a period of 8 weeks. At the same time take hypolipidemic drug probucol tablets 0.5g, 1 day 2 times. Before and after treatment for 24 hours to check the ambulatory blood pressure monitoring and lipid five. Statistical analysis and correlation analysis. Results: AASI and AIP decreased significantly after 8 weeks of application. There was a significant positive correlation between AASI and AIP, which effectively delayed and controlled the development of cardiovascular diseases such as hypertension and arteriosclerosis, and reduced cardiovascular risk factors and target organ damage. Also suggests that AASI, AIP is the clinical prevention and treatment of hypertension and arteriosclerosis as well as the clinical risk factors for hypertension early intervention measures to observe the effective and sensitive indicators.